Pfizer (NYSE:PFE) Announces Earnings Results

Pfizer (NYSE:PFE) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09, Briefing.com reports. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 earnings per share.

Pfizer Price Performance

Shares of PFE opened at $26.68 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $25.54 and its 200-day simple moving average is $25.05. The firm has a market capitalization of $151.67 billion, a price-to-earnings ratio of 15.51 and a beta of 0.47. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s payout ratio is currently 100.00%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. Scotiabank initiated coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Bank of America decreased their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. HSBC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Finally, Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.06.

Institutional Trading of Pfizer

Institutional investors and hedge funds have recently bought and sold shares of the business. Quest Investment Management LLC boosted its holdings in Pfizer by 1.3% in the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 405 shares in the last quarter. WealthCollab LLC lifted its holdings in Pfizer by 12.5% in the second quarter. WealthCollab LLC now owns 3,985 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 442 shares during the period. Abel Hall LLC increased its holdings in shares of Pfizer by 1.7% in the 3rd quarter. Abel Hall LLC now owns 26,342 shares of the biopharmaceutical company’s stock valued at $671,000 after purchasing an additional 442 shares in the last quarter. Vivaldi Capital Management LP lifted its stake in shares of Pfizer by 3.4% in the second quarter. Vivaldi Capital Management LP now owns 14,438 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 472 shares during the period. Finally, Guardian Investment Management increased its stake in Pfizer by 4.1% in the 3rd quarter. Guardian Investment Management now owns 14,310 shares of the biopharmaceutical company’s stock valued at $365,000 after purchasing an additional 558 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat consensus ($0.66 EPS vs. ~ $0.56–$0.57 expected) and margins held up, showing underlying demand for legacy drugs like Eliquis offsetting COVID declines. Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: Pfizer reported Phase 2b results for its ultra?long?acting injectable GLP?1 (PF’3944 / MET?097i) showing around 12–12.3% weight loss with monthly dosing — a meaningful pipeline win that supports future growth beyond COVID-era sales. Pfizer’s Ultra?Long?Acting Injectable GLP?1 RA Shows Robust and Continued Weight Loss
• Positive Sentiment: Pfizer is pursuing vaccine refresh opportunities (using Novavax’s Matrix?M adjuvant) to bolster its vaccine pipeline and potential future vaccine revenue. Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story
• Neutral Sentiment: The company reaffirmed its modest 2026 outlook — reducing surprise risk but signaling limited upside in the near term. Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
• Neutral Sentiment: Analyst moves were mixed: Cantor raised its price target to $27 (reflecting pipeline optimism) while Goldman Sachs remains Neutral, citing rising margin pressure from upcoming patent losses. Cantor Fitzgerald Raises Pfizer PT to $27 Goldman Sachs Maintains Neutral on Pfizer
• Negative Sentiment: Management warned of near?term profit declines and flagged a material impact from patent expirations (analysts cite roughly a $1.5B headwind), which pressures 2026 revenue and margins. Pfizer projects annual revenue decline amid $1.5B hit from patent cliffs
• Negative Sentiment: Despite the positives, the stock slipped as investors focused on margin pressure, policy/pricing headwinds and the need for cost cuts to offset declines — raising short?term risk to the share price. Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.